JP6223376B2 - Ｇｉｐ上昇抑制剤の評価又は選択方法 - Google Patents

Ｇｉｐ上昇抑制剤の評価又は選択方法 Download PDF

Info

Publication number
JP6223376B2
JP6223376B2 JP2015040187A JP2015040187A JP6223376B2 JP 6223376 B2 JP6223376 B2 JP 6223376B2 JP 2015040187 A JP2015040187 A JP 2015040187A JP 2015040187 A JP2015040187 A JP 2015040187A JP 6223376 B2 JP6223376 B2 JP 6223376B2
Authority
JP
Japan
Prior art keywords
fabp4
protein
fabp5
expression level
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015040187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015194481A (ja
JP2015194481A5 (cg-RX-API-DMAC10.html
Inventor
義隆 古賀
義隆 古賀
紀子 大崎
紀子 大崎
渡邊　学
学 渡邊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2015040187A priority Critical patent/JP6223376B2/ja
Priority to CN201580015560.7A priority patent/CN106133519B/zh
Priority to US15/128,666 priority patent/US10132795B2/en
Priority to PCT/JP2015/056603 priority patent/WO2015146537A1/ja
Priority to EP15769760.8A priority patent/EP3124966B1/en
Publication of JP2015194481A publication Critical patent/JP2015194481A/ja
Publication of JP2015194481A5 publication Critical patent/JP2015194481A5/ja
Application granted granted Critical
Publication of JP6223376B2 publication Critical patent/JP6223376B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015040187A 2014-03-24 2015-03-02 Ｇｉｐ上昇抑制剤の評価又は選択方法 Expired - Fee Related JP6223376B2 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2015040187A JP6223376B2 (ja) 2014-03-24 2015-03-02 Ｇｉｐ上昇抑制剤の評価又は選択方法
CN201580015560.7A CN106133519B (zh) 2014-03-24 2015-03-06 Gip上升抑制剂的评价或选择方法
US15/128,666 US10132795B2 (en) 2014-03-24 2015-03-06 Method for evaluating or selecting agent for suppressing GIP level elevation
PCT/JP2015/056603 WO2015146537A1 (ja) 2014-03-24 2015-03-06 Ｇｉｐ上昇抑制剤の評価又は選択方法
EP15769760.8A EP3124966B1 (en) 2014-03-24 2015-03-06 Method for evaluating or selecting agent for suppressing gip level elevation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014060341 2014-03-24
JP2014060341 2014-03-24
JP2015040187A JP6223376B2 (ja) 2014-03-24 2015-03-02 Ｇｉｐ上昇抑制剤の評価又は選択方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017144146A Division JP6514282B2 (ja) 2014-03-24 2017-07-26 Ｇｉｐ上昇抑制剤の評価又は選択方法

Publications (3)

Publication Number Publication Date
JP2015194481A JP2015194481A (ja) 2015-11-05
JP2015194481A5 JP2015194481A5 (cg-RX-API-DMAC10.html) 2017-04-06
JP6223376B2 true JP6223376B2 (ja) 2017-11-01

Family

ID=54195063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015040187A Expired - Fee Related JP6223376B2 (ja) 2014-03-24 2015-03-02 Ｇｉｐ上昇抑制剤の評価又は選択方法

Country Status (5)

Country Link
US (1) US10132795B2 (cg-RX-API-DMAC10.html)
EP (1) EP3124966B1 (cg-RX-API-DMAC10.html)
JP (1) JP6223376B2 (cg-RX-API-DMAC10.html)
CN (1) CN106133519B (cg-RX-API-DMAC10.html)
WO (1) WO2015146537A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6677455B2 (ja) * 2015-05-14 2020-04-08 花王株式会社 毛成長抑制剤の評価又は選択方法
CN114981446A (zh) * 2020-01-17 2022-08-30 日本乐敦制药株式会社 组织形态、组织功能控制剂的评价/筛选方法
CN116908157B (zh) * 2023-07-14 2026-05-29 杭州环特生物科技股份有限公司 一种评价药物和保健食品调节食欲的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
EE200100155A (et) 1998-09-17 2002-08-15 Bristol-Myers Squibb Company Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
JP2004065194A (ja) * 2002-08-09 2004-03-04 Sumitomo Chem Co Ltd 脂肪細胞関連因子の分析方法
PT2403605E (pt) 2009-03-05 2015-08-05 Harvard College Composições contendo um anticorpo específico de ap2 ou um seu fragmento, para serem utilizadas no tratamento de diabetes, intolerância à glicose ou resistência à insulina induzida por obesidade
JP5815928B2 (ja) 2009-07-16 2015-11-17 花王株式会社 血中ｇｉｐ濃度上昇抑制剤
JP5317919B2 (ja) 2009-10-05 2013-10-16 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP5328595B2 (ja) * 2009-10-05 2013-10-30 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
US9056066B2 (en) 2011-01-12 2015-06-16 Kao Corporation Agent for suppressing elevation of blood GIP level, agent for suppressing elevation of blood insulin level, agent for lowering blood triglyceride level after meal ingestion, and agent for suppressing elevation of blood glucose level
JP6026723B2 (ja) 2011-02-22 2016-11-16 花王株式会社 Ｇｉｐ上昇抑制剤
JP2012171914A (ja) 2011-02-22 2012-09-10 Kao Corp Ｇｉｐ上昇抑制剤
CN102961388A (zh) 2011-08-30 2013-03-13 三和淀粉工业株式会社 促进glp-1的分泌并且抑制gip的分泌的药剂

Also Published As

Publication number Publication date
WO2015146537A1 (ja) 2015-10-01
EP3124966A4 (en) 2017-09-27
EP3124966A1 (en) 2017-02-01
US20170227526A1 (en) 2017-08-10
JP2015194481A (ja) 2015-11-05
EP3124966B1 (en) 2020-04-29
US10132795B2 (en) 2018-11-20
CN106133519A (zh) 2016-11-16
CN106133519B (zh) 2018-01-09

Similar Documents

Publication Publication Date Title
Zadjali et al. SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high‐fat‐diet‐fed mice
McLean et al. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation
Heida et al. The hepatocyte IKK: NF-κB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis
Hansotia et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Nishio et al. Hepatic vagus nerve regulates Kupffer cell activation via α7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitis
Kosteli et al. Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue
Kim et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue
Liou et al. The G-protein− coupled receptor GPR40 directly mediates long-chain fatty acid− induced secretion of cholecystokinin
Wu et al. The role of hepassocin in the development of non-alcoholic fatty liver disease
Nguyen et al. Very low density lipoprotein receptor (VLDLR) expression is a determinant factor in adipose tissue inflammation and adipocyte-macrophage interaction
Ström et al. Attainment of brown adipocyte features in white adipocytes of hormone-sensitive lipase null mice
Chandra et al. Immunoglobulin-like domain containing receptor 1 mediates fat-stimulated cholecystokinin secretion
Lee et al. CREB/CRTC2 controls GLP‐1‐dependent regulation of glucose homeostasis
Arifin et al. Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119
Jain et al. Hip1r is expressed in gastric parietal cells and is required for tubulovesicle formation and cell survival in mice
Yang et al. Family with sequence similarity 3 gene family and nonalcoholic fatty liver disease
Hayashi et al. Adipose-specific CC motif chemokine ligand (CCL) 19 overexpression drives the mice to both insulin resistance and weight gain
JP2015194481A (ja) Ｇｉｐ上昇抑制剤の評価又は選択方法
Majchrzak et al. Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for the treatment of Obesity-Associated cancers
Ferreira et al. Messages from the small intestine carried by extracellular vesicles in prediabetes: A proteomic portrait
Kiefer et al. Intestinal retinol saturase is implicated in the development of obesity and epithelial homeostasis upon injury
JP6514282B2 (ja) Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6442403B2 (ja) 代謝調節のための方法および組成物
Zhang et al. Uncoupling protein 2 negatively regulates glucose-induced glucagon-like peptide 1 secretion
Tsai et al. CCAAT/enhancer binding protein-δ expression by dendritic cells regulates CNS autoimmune inflammatory disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170303

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20170303

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20170317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171003

R151 Written notification of patent or utility model registration

Ref document number: 6223376

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees